Project, program, and portfolio risk analysis
- Location: Hilton London Kensington, 179-199 Holland Park Avenue, London W11 4UL, United Kingdom
- March 5-6, 2024
- 8:00 - 17:00 Local Time
-
Course Leader: Dr. Richard Bayney,
President & Founder of Project & Portfolio Value Creation.
MASTERCLASS OVERVIEW
Learn how to quantify and manage risk at project, program, and portfolio levels. Assess the extent to which multiple indications and/or lines of therapy affect program risk and valuation. Quantify the likelihood that your R&D pipeline portfolio and commercial portfolio will meet annual corporate targets
AUDIENCE
- Project, Program & Portfolio Management
- Research
- Clinical Development
- Resource Management
- Forecasting & Competitive Intelligence
- Licensing & Business Development
- Finance
- Commercialization
- Consultants are NOT permitted to attend
Masterclassleader
Dr. Richard Bayney is President of Project & Portfolio Value Creation (PPVC), a consulting boutique that he founded in 2008 which provides training and education in Project, Program, Portfolio, Resource, and Risk Management as well as Business, Strategic, Portfolio, and Scenario Planning services. He is an adjunct faculty member at the University of Pennsylvania.
Dr. Bayney is a 23-year veteran of the Pharmaceutical & Biotechnology industry at Merck & Co., Bayer Corp. and AG, Bristol-Myers Squibb, and Johnson & Johnson Pharmaceutical Research & Development. In his previous position at Johnson & Johnson, Richard was Vice President, Portfolio Management & Decision Analysis. Dr. Bayney obtained his M.Sc. and Ph.D. from the University of London, MBA from Columbia University, and PMP from the Project Management Institute.
DR. Richard Bayney’s
Personal invitation
TOPIC SNEAK PEEK
- Quantification of project risk using risk decomposition and Decision Trees
- Quantification of program risk using correlated project risks and Decision Trees
- Quantification of portfolio risk using simulation
- Generation of strategic alternatives for Clinical Development, Registration, and Commercialization
- Selecting dominant strategies based on eNPV
- Accounting for commercial uncertainty in the product portfolio using simulation
- Accounting for risk and commercial uncertainty in the pipeline portfolio
- Quantifying the likelihood of meeting corporate growth targets (Long Range Plan)
REGISTRATION
Conference
Ticket | March 7-8, 2024-
Access to All Conference Sessions
-
Access to Post Conferences Networking
-
Conference Materials
-
Includes Coffee Breaks, Snacks and Refreshments, Seated Lunch
Masterclass
Ticket | March 5-6, 2024-
Renowned Project, program, and portfolio risk analysis Masterclass with Industry Veteran Richard Bayney
-
One-on-one coaching
-
Copy of 2022's “The State of Portfolio Management” Benchmark Report
-
Design sessions for direct application
-
Benchmarks to identify your organization's performance gaps
Masterclass + Conference
Ticket | March 5-8, 2024-
Grants all Masterclass and Conference Ticket Benefits including access to the Project, program, and portfolio risk analysis Masterclass + 26th European Pharma And Biotech Project, Program And Portfolio Management Conference at a special rate.